Neurodegenerative diseases are characterized by a loss of neuronal structure and function that leads to problems with movement (ataxis) or mental function (dementia). These changes occur due to genetic mutations or protein folding disorders that can accumulate with age. While pathophysiologies like amyloid plaques are well documented, many of the cellular processes that drive neurodegeneration have yet to be fully elucidated. Defects in these key processes may be shared among different neurodegenerative diseases, making it likely that new therapies targeting one process may alleviate the progression of many conditions.
CST has put together a starter’s guide on the cellular mechanisms that drive neurodegeneration in diseases such as Alzheimer’s Disease, Parkinson’s Disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington’s Disease. Wondering how to identify the many different cell types that make up the Central Nervous System (CNS)? CST also has a Cell Type Marker Guide! At the end of the guide.
Topics of the guide:
- Protein Folding and Aggregation
- Altered Cell Signaling
- Altered Epigenetics
- Altered Metabolism
- Acquiring Cell Death
- Acquiring Senescence
- Neuronal, Astrocyte, and Oligodendrocyte Markers
- Microglial Markers
Solutions to Advance Your Neurodegeneration Therapeutics Discovery
Put CST’s experience to work for you. CST experts keep up with the latest research and neurodegenerative disease treatment approaches to develop a broad portfolio of antibodies, ready-to-use kits, and custom services that could lead to new, more efficacious therapies. Download the Solutions for Advancing Neurodegeneration Therapeutics Discovery brochure and learn about:
Solutions for assay development
Solutions across the drug development continuum
Cellular targets in therapeutic development
Cell characterization markers
Download the product flyer to get the latest products for Neurodegeneration (NDG) research broken down by the top disease areas (Alzheimer's Disease, AD and Parkinson's Disease, PD) etc.